Ermolenko Elena, Baryshnikova Natalia, Alekhina Galina, Zakharenko Alexander, Ten Oleg, Kashchenko Victor, Novikova Nadezhda, Gushchina Olga, Ovchinnikov Timofey, Morozova Anastasia, Ilina Anastasia, Karaseva Alena, Tsapieva Anna, Gladyshev Nikita, Dmitriev Alexander, Suvorov Alexander
Scientific and Educational Center "Molecular Bases of Interaction of Microorganisms and Human", World-Class Research Center "Center for Personalized Medicine", Institute of Experimental Medicine, 197376 St-Petersburg, Russia.
Department of Internal Disease of Stomatology Faculty, Pavlov First St-Petersburg State Medical University, 197022 St-Petersburg, Russia.
Microorganisms. 2024 May 13;12(5):980. doi: 10.3390/microorganisms12050980.
Despite great advances in the treatment of oncological diseases, the development of medical technologies to prevent or reduce complications of therapy, in particular, those associated with surgery and the introduction of antibiotics, remains relevant. The aim of this study is to evaluate the effectiveness of the use of autoprobiotics based on indigenous non-pathogenic strains of and as a personalized functional food product (PFFP) in the complex therapy of colorectal cancer (CRC) in the early postoperative period. A total of 36 patients diagnosed with CRC were enrolled in the study. Study group A comprised 24 CRC patients who received autoprobiotic therapy in the early postoperative period, while the control group C included 12 CRC patients without autoprobiotic therapy. Prior to surgery and between days 14 and 16 post-surgery, comprehensive evaluations were conducted on all patients, encompassing the following: stool and gastroenterological complaints analysis, examination of the gut microbiota (bacteriological study, quantitative polymerase chain reaction, metagenome analysis), and analysis of interleukins in the serum. Results: The use of autoprobiotics led to a decrease in dyspeptic complaints after surgery. It was also associated with the absence of postoperative complications, did not cause any side effects, and led to a decrease in the level of pro-inflammatory cytokines (IL-6 and IL-18) in the blood serum. The use of autoprobiotics led to positive changes in the structure of escherichia and enterococci populations, the elimination of and , and a decrease in the quantitative content of and . Metagenomic analysis (16S rRNA) revealed an increase in alpha diversity. Conclusion: The introduction of autoprobiotics in the postoperative period is a highly effective and safe approach in the complex treatment of CRC. Future studies will allow the discovery of additional fine mechanisms of autoprobiotic therapy and its impact on the digestive, immune, endocrine, and neural systems.
尽管肿瘤疾病的治疗取得了巨大进展，但开发预防或减少治疗并发症的医疗技术仍然具有重要意义，特别是与手术和抗生素使用相关的并发症。本研究的目的是评估基于本地非致病菌株的自生益生菌作为个性化功能性食品（PFFP）在结直肠癌（CRC）术后早期综合治疗中的有效性。共有36例诊断为CRC的患者纳入本研究。研究组A包括24例在术后早期接受自生益生菌治疗的CRC患者，而对照组C包括12例未接受自生益生菌治疗的CRC患者。在手术前以及术后第14天至16天之间，对所有患者进行了全面评估，包括：粪便和胃肠疾病主诉分析、肠道微生物群检查（细菌学研究、定量聚合酶链反应、宏基因组分析）以及血清白细胞介素分析。结果：使用自生益生菌可减少术后消化不良主诉。它还与无术后并发症相关，未引起任何副作用，并导致血清中促炎细胞因子（IL-6和IL-18）水平降低。使用自生益生菌导致大肠杆菌和肠球菌种群结构发生积极变化，消除了某些菌种，并降低了其他菌种的定量含量。宏基因组分析（16S rRNA）显示α多样性增加。结论：术后引入自生益生菌是CRC综合治疗中一种高效且安全的方法。未来的研究将有助于发现自生益生菌治疗的更多精细机制及其对消化、免疫、内分泌和神经系统的影响。
